Transplantation details of patients with POEMS syndrome who underwent ASCT
| . | Number, N = 59 (%) . | No progression, N = 45 (%) . | Progression, N = 14 (%) . |
|---|---|---|---|
| Stem cell mobilization | |||
| Cyclophosphamide/growth factor | 6 (10) | 4 (9) | 2 (14) |
| Growth factor alone | 50 (85) | 38 (84) | 12 (86) |
| Growth factor/plerixafor | 3 (5) | 3 (7) | 0 |
| Conditioning regimen | |||
| Melphalan, 200 mg/m2 | 41 (69) | 29 (64) | 12* (86) |
| Melphalan, 140 mg/m2 | 17 (29) | 15 (33) | 2 (14) |
| BEAM | 1 (2) | 1 (2) | 0 |
| Median stem cell dose, ×106 CD34 cells/kg (IQR) | 4.4 (3.7-5.3) | 4.4 (3.7-5.2) | 4.9 (3.3-5.9) |
| Median days in hospital (range) | 9 (0-175) | 9 (0-175) | 3.5 (0-20) |
| Periengraftment syndrome | 22 (37) | 19 (42) | 3 (21) |
| Engraftment days (IQR) | |||
| Neutrophils | 15 (11-35) | 15 (14-17) | 16 (15-19) |
| Platelets > 20 000 | 13 (8-26) | 14 (12-18) | 11 (11-14) |
| Platelets > 50 000 | 15 (11-28) | 16 (14-19) | 15 (13-17) |
| . | Number, N = 59 (%) . | No progression, N = 45 (%) . | Progression, N = 14 (%) . |
|---|---|---|---|
| Stem cell mobilization | |||
| Cyclophosphamide/growth factor | 6 (10) | 4 (9) | 2 (14) |
| Growth factor alone | 50 (85) | 38 (84) | 12 (86) |
| Growth factor/plerixafor | 3 (5) | 3 (7) | 0 |
| Conditioning regimen | |||
| Melphalan, 200 mg/m2 | 41 (69) | 29 (64) | 12* (86) |
| Melphalan, 140 mg/m2 | 17 (29) | 15 (33) | 2 (14) |
| BEAM | 1 (2) | 1 (2) | 0 |
| Median stem cell dose, ×106 CD34 cells/kg (IQR) | 4.4 (3.7-5.3) | 4.4 (3.7-5.2) | 4.9 (3.3-5.9) |
| Median days in hospital (range) | 9 (0-175) | 9 (0-175) | 3.5 (0-20) |
| Periengraftment syndrome | 22 (37) | 19 (42) | 3 (21) |
| Engraftment days (IQR) | |||
| Neutrophils | 15 (11-35) | 15 (14-17) | 16 (15-19) |
| Platelets > 20 000 | 13 (8-26) | 14 (12-18) | 11 (11-14) |
| Platelets > 50 000 | 15 (11-28) | 16 (14-19) | 15 (13-17) |
POEMS represents polyradiculoneuropathy, organomegaly, multiple endocrinopathies, monoclonal protein, and a myriad of skin changes such as hypertrichosis, skin thickening, cherry angiomata, and hyperpigmentation; ASCT, autologous stem cell transplantation; 153Sm-EDTMP, samarium-153 ethylene diamine tetramethylene diphosphonate; BEAM, carmustine, etoposide, cytarabine, melphalan; and IQR, interquartile range.
One patient got 153Sm-EDTMP with melphalan.